BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP
6211 results:

  • 1. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board.
    Horn IP; Zakas AL; Smith-Simmer KJ; Birkeland LE; Sundstrom R; Burkard ME; Weiss JM
    JCO Precis Oncol; 2024 May; 8():e2300466. PubMed ID: 38810171
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in advanced ovarian cancer.
    Park K; Kwon JY; Song JM; Pyeon SY; Lee SH; Chung YS; Lee JM
    PLoS One; 2024; 19(5):e0299205. PubMed ID: 38805507
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Epithelial ovarian cancer and brain metastases: might the
    Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
    Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Epigenetic editing of
    He W; Zhu H; Zhang S; Shu G; Lei H; Wang M; Yin G; Ni X; Wu Q
    Epigenetics; 2024 Dec; 19(1):2357518. PubMed ID: 38796857
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Analysis of brca1 germline variants (exons 5, 11 and 20) in breast cancer families from Libya.
    Elmaihub ES; Alhudiri I; Ramadan AM; Eljilani M; Elzagheid A; Elfagi F; Hassen E
    Libyan J Med; 2024 Dec; 19(1):2356906. PubMed ID: 38785139
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. brca1/BARD1 ubiquitinates PCNA in unperturbed conditions to promote continuous DNA synthesis.
    Salas-Lloret D; García-Rodríguez N; Soto-Hidalgo E; González-Vinceiro L; Espejo-Serrano C; Giebel L; Mateos-Martín ML; de Ru AH; van Veelen PA; Huertas P; Vertegaal ACO; González-Prieto R
    Nat Commun; 2024 May; 15(1):4292. PubMed ID: 38769345
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
    Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
    Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
    BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
    Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
    Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Blood Lead Level as Marker of Increased Risk of ovarian cancer in brca1 Carriers.
    Kiljańczyk A; Matuszczak M; Marciniak W; Derkacz R; Stempa K; Baszuk P; Bryśkiewicz M; Lubiński K; Cybulski C; Dębniak T; Gronwald J; Huzarski T; Lener MR; Jakubowska A; Szwiec M; Stawicka-Niełacna M; Godlewski D; Prusaczyk A; Jasiewicz A; Kluz T; Tomiczek-Szwiec J; Kilar-Kobierzycka E; Siołek M; Wiśniowski R; Posmyk R; Jarkiewicz-Tretyn J; Sun P; Scott RJ; Narod SA; Lubiński J
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732616
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
    Andaluz S; Zhao B; Sinha S; Lagniton PNP; Costa DA; Ding X; Brito M; Wang SM
    BMC Genomics; 2024 Apr; 25(1):416. PubMed ID: 38671360
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer.
    Hu D; Qian J; Yin F; Wei B; Wang J; Zhang H; Yang H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():170-175. PubMed ID: 38663180
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Mechanism of single-stranded DNA annealing by RAD52-RPA complex.
    Liang CC; Greenhough LA; Masino L; Maslen S; Bajrami I; Tuppi M; Skehel M; Taylor IA; West SC
    Nature; 2024 May; 629(8012):697-703. PubMed ID: 38658755
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Germline mutations in brca1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
    de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
    BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast cancer-Associated Germline Pathogenic Variants in Mexico.
    Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
    JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A Study on the Retrospective Reinterpretation of brca1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
    Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
    Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
    Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
    JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.
    Motonari T; Yoshino Y; Haruta M; Endo S; Sasaki S; Miyashita M; Tada H; Watanabe G; Kaneko T; Ishida T; Chiba N
    Sci Rep; 2024 Apr; 14(1):7519. PubMed ID: 38589490
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 311.